Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its

Shuai Yuan1, Ang Lin2, Qi-Qiang He3

  • 1Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Insights

Interleukin-6 (IL-6) inhibition may prevent cardiovascular diseases like coronary artery disease (CAD) and atrial fibrillation (AF). However, increased Interleukin-1 receptor antagonist (IL-1ra) levels may raise the risk for CAD and cardioembolic stroke.

Area of Science:

  • Genetics
  • Immunology
  • Cardiovascular Medicine

Background:

  • The precise role of interleukins (ILs) in cardiovascular disease pathogenesis remains unclear.
  • Investigating the causal links between circulating ILs and major cardiovascular outcomes is crucial for therapeutic development.

Purpose of the Study:

  • To explore the associations between genetically predicted circulating levels of various interleukins and the risk of coronary artery disease (CAD), atrial fibrillation (AF), and ischemic stroke.
  • To elucidate the specific causal roles of different ILs in cardiovascular disease development.

Main Methods:

  • A Mendelian randomization study design was employed.
  • Genome-wide association studies identified single-nucleotide polymorphisms (SNPs) associated with IL-1β, IL-1 receptor antagonist (IL-1ra), IL-2 receptor subunit alpha, IL-6, IL-16, IL-17, and IL-18.
  • Summary-level genetic data from large consortia were used for outcome association analyses.

Main Results:

  • Genetically elevated IL-1ra levels showed a significant association with increased CAD risk (OR=1.36).
  • Genetically elevated IL-6 levels, particularly those associated with reduced bio-function, were inversely associated with CAD (OR=0.64) and AF (OR=0.70).
  • Suggestive associations were observed for IL-1ra with cardioembolic stroke and IL-6 with various ischemic stroke subtypes; IL-16 showed a suggestive inverse association with CAD.

Conclusions:

  • Findings support IL-6 inhibition as a potential therapeutic strategy for preventing CAD, AF, and ischemic stroke.
  • Elevated IL-1ra levels suggest a potential increased risk for CAD and cardioembolic stroke, indicating a possible detrimental role of IL-1 pathway activation.
  • The association of IL-16 with CAD warrants further investigation.
Abstract

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
297
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
150
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
789
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
363
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
680
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
593